FIGURE 6.
Incidence of hypothalamic-pituitary axis (HPA) suppression in maximal use safety study of clobetasol propionate 0.025% cream vs. 0.05% cream twice daily for 14 days; mean body surface area (BSA) 26.5–27%
Incidence of hypothalamic-pituitary axis (HPA) suppression in maximal use safety study of clobetasol propionate 0.025% cream vs. 0.05% cream twice daily for 14 days; mean body surface area (BSA) 26.5–27%